Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PF-06480605 Clear all

Conditions: Moderately to Severely Active Ulcerative Colitis
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 46
States / cities: Dothan, Alabama • Lancaster, California • Orange, California + 39 more

Conditions: Healthy
Interventions: PF-06480605, Placebo; Drug
Lead sponsor: Telavant, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Rheumatoid Arthritis
Interventions: Afimkibart; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 5
States / cities: Tamarac, Florida • Lake Charles, Louisiana • Houston, Texas + 2 more

Conditions: Rheumatoid Arthritis
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Avondale, Arizona • Peoria, Arizona • La Jolla, California + 15 more

Conditions: Moderately to Severely Active Ulcerative Colitis
Interventions: Afimkibart; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 8
States / cities: Aurora, Colorado • Hartford, Connecticut • Tampa, Florida + 5 more

Conditions: Active Ulcerative Colitis
Interventions: Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Chula Vista, California • Miami, Florida

Conditions: Atopic Dermatitis
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Fremont, California • Los Angeles, California • Fort Myers, Florida + 16 more

Conditions: MASH
Interventions: RO7790121; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 11
States / cities: Tucson, Arizona • Marietta, Georgia • Bastrop, Louisiana + 8 more

Conditions: Moderately to Severely Active Crohns Disease
Interventions: Afimkibart; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Moderate to Severe Ulcerative Colitis
Interventions: Induction- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W, Induction- PF-06480605 450 mg SC Q4W, Induction- Placebo SC Q4W, Chronic- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 55
States / cities: Dothan, Alabama • Little Rock, Arkansas • Newport Beach, California + 20 more

Conditions: Moderately to Severely Active Ulcerative Colitis
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 64
States / cities: Dothan, Alabama • Scottsdale, Arizona • Sun City, Arizona + 52 more

Conditions: Crohns Disease
Interventions: Afimkibart; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Dothan, Alabama • Hamden, Connecticut • Kissimmee, Florida + 2 more

Conditions: Colitis, Ulcerative
Interventions: PF-06480605; Drug
Lead sponsor: Telavant, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Aventura, Florida • North Miami Beach, Florida • Pembroke Pines, Florida + 5 more

Conditions: Atopic Dermatitis
Interventions: Afimkibart; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 7
States / cities: Los Angeles, California • Tampa, Florida • Alpharetta, Georgia + 3 more

Conditions: Moderately to Severely Active Crohns Disease
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 61
States / cities: Dothan, Alabama • Glendale, Arizona • Lancaster, California + 55 more

Conditions: Moderately to Severely Active Crohns Disease
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 95
States / cities: Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 79 more

Search by objective public record fields.

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease